AstraZeneca Defeats Canada's Patent 'Promise Doctrine' Through Court, Not NAFTA
Executive Summary
Supreme Court of Canada says promise doctrine is not correct approach to determine if a patent has sufficient utility; doctrine has been used to invalidate patents on 22 medicines.
You may also be interested in...
Pharma Patents Are Vulnerable In Canada As Lilly Loses NAFTA Challenge
Tribunal finds Lilly did not prove that Canada's promise utility doctrine discriminates against pharmaceutical patents; 25 pharma patents have been invalidated in past decade.
O Canada! Lilly Claims Country’s Invalidation Of Its Patents Violates NAFTA
Lilly is seeking $500 million for revenue it would have made if Canadian courts had not ruled its Zyprexa and Strattera patents invalid; company says Canada’s new “promise utility doctrine” is targeting pharma inventions.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.